Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Akorn Inc (AKRX)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 375,478
  • Shares Outstanding, K 125,578
  • Annual Sales, $ 694,020 K
  • Annual Income, $ -401,910 K
  • 60-Month Beta 2.75
  • Price/Sales 0.50
  • Price/Cash Flow 8.09
  • Price/Book 0.78

Analyst Rating / Earnings Estimates

Current Rating
See More
Hold
Based on 5 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/19
See More
  • Average Estimate -0.11
  • Number of Estimates 3
  • High Estimate -0.02
  • Low Estimate -0.17
  • Prior Year N/A
  • Growth Rate Est. (year over year) -100.01%

Price Performance

See More
Period Period Low Period High Performance
1-Month
2.67 +11.61%
on 04/18/19
3.64 -18.13%
on 04/01/19
-0.52 (-14.86%)
since 03/22/19
3-Month
2.67 +11.61%
on 04/18/19
4.55 -34.51%
on 02/20/19
-0.87 (-22.60%)
since 01/23/19
52-Week
2.67 +11.61%
on 04/18/19
19.65 -84.83%
on 08/08/18
-10.07 (-77.16%)
since 04/23/18

Most Recent Stories

More News
Glancy Prongay & Murray LLP Files a Securities Class Action Notifying Investors of Expanded Class Period (AKRX)

Glancy Prongay & Murray LLP("GPM")announces that it has filed a class action lawsuit in the United States District Court for the Northern District of Illinois, captioned Juan v. Akorn...

AKRX : 2.98 (-0.33%)
FINAL DEADLINE ALERT - AKRX, HIIQ & AMRN - Bronstein, Gewirtz & Grossman, LLC

Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against the following publicly-traded companies. You can review a copy of the Complaints...

AMRN : 18.39 (+1.32%)
HIIQ : 26.12 (+5.11%)
AKRX : 2.98 (-0.33%)
Glancy Prongay & Murray Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Akorn, Inc.

Glancy Prongay & Murray LLP ("GPM") reminds investors of the April 22, 2019 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased Akorn, Inc. ("Akorn"...

AKRX : 2.98 (-0.33%)
Block & Leviton LLP Reminds Shareholders of Important Deadlines: AKRX, SYNH, INGN, BPI

Block & Leviton LLP (www.blockesq.com), a securities litigation firm representing investors nationwide, reminds investors of the important deadlines listed below. If you have purchased or otherwise acquired...

ZVO : 5.95 (+0.51%)
SYNH : 46.93 (+2.11%)
AKRX : 2.98 (-0.33%)
INGN : 84.04 (+6.57%)
Akorn Receives FDA Approval for Loteprednol Etabonate Ophthalmic Suspension, 0.5%

Akorn, Inc. (Nasdaq: AKRX), a leading specialty generic pharmaceutical company, today announced that it received a new Abbreviated New Drug Application (ANDA) approval from the U.S. Food and Drug Administration...

AKRX : 2.98 (-0.33%)
Innovus Pharma Announces FDA Approval of New ANDA for Supply of FlutiCare(R)

Innovus Pharmaceuticals, Inc. ("Innovus Pharma" or the "Company") (OTCQB Venture Market: INNV), an emerging commercial-stage pharmaceutical company that delivers safe, innovative and effective...

AKRX : 2.98 (-0.33%)
INNV : 3.5900 (-4.27%)
APRIL 22 DEADLINE: Pawar Law Group Announces a Securities Class Action Lawsuit Against Akorn, Inc. - AKRX

Pawar Law Group announces that a class action lawsuit has been filed on behalf of shareholders who purchased shares of Akorn, Inc. (NASDAQ: AKRX) from August 1, 2018 through January 8, 2019, inclusive...

AKRX : 2.98 (-0.33%)
Glancy Prongay & Murray Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Akorn, Inc.

Glancy Prongay & Murray LLP ("GPM") reminds investors of the April 22, 2019 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased Akorn, Inc. ("Akorn"...

AKRX : 2.98 (-0.33%)
AKORN APRIL 22nd DEADLINE: Rosen Law Firm Reminds Akorn, Inc. Investors of Important Deadline in Securities Class Action Lawsuit Filed by the Firm - AKRX

Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Akorn, Inc. from August 1, 2018 through January 8, 2019, inclusive (the "Class Period") of the important April...

AKRX : 2.98 (-0.33%)
Block & Leviton LLP Reminds Shareholders of Important Deadlines: TAP, AKRX, SYNH, CTL

Block & Leviton LLP (www.blockesq.com), a securities litigation firm representing investors nationwide, reminds investors of the important deadlines listed below. If you have purchased or otherwise acquired...

TAP : 61.28 (+0.20%)
SYNH : 46.93 (+2.11%)
CTL : 11.87 (-0.08%)
AKRX : 2.98 (-0.33%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 72% Sell with a Weakest short term outlook on maintaining the current direction.

Longer term, the trend strength is Average. Long term indicators fully support a continuation of the trend.

See More Share

Trade AKRX with:

Business Summary

Akorn, Inc. is a specialty generic pharmaceutical company engaged in the development, manufacture and marketing of multisource and branded pharmaceuticals. They specialize in difficult-to-manufacture sterile and non-sterile dosage forms including: ophthalmics, injectables, oral liquids, otics, topicals,...

See More

Key Turning Points

2nd Resistance Point 3.17
1st Resistance Point 3.08
Last Price 2.98
1st Support Level 2.80
2nd Support Level 2.62

See More

52-Week High 19.65
Fibonacci 61.8% 13.16
Fibonacci 50% 11.16
Fibonacci 38.2% 9.16
Last Price 2.98
52-Week Low 2.67

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar